Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 2;6(1):vdae138.
doi: 10.1093/noajnl/vdae138. eCollection 2024 Jan-Dec.

Survival probability of epigenetically defined IDH-wild-type glioblastoma without necrosis or vascular proliferation

Patrick N Harter  1   2 , Katharina J Weber  3   4   5   6 , Franz L Ricklefs  7 , Richard Drexler  7 , Ulrich Schüller  8   9   10 , Marcel Hack  2 , Tim Hanke  2 , Hildegard Dohmen  11 , Till Acker  11 , Andreas von Deimling  12   13 , Martin Hasselblatt  14 , Iris Divé  15   16   3   4   5 , Kristian Unger  17   18   1 , Joachim P Steinbach  15   16   3   4   5 , David Capper  19   20 , Michael W Ronellenfitsch  15   16   3   4   5
Affiliations

Survival probability of epigenetically defined IDH-wild-type glioblastoma without necrosis or vascular proliferation

Patrick N Harter et al. Neurooncol Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest with the content of the present study.

Figures

Figure 1.
Figure 1.
(A) Stratification of both cohorts by RT/CT (missing data for 42 patients). (B) Distribution of the variable “contrast enhancement” in both cohorts. Overall survival with regard to “contrast enhancement” (CE) in the entire cohort (C) and in patients that received RT/CT (D). Kaplan–Meier survival curves of the cohorts included only patients who received RT/CT (E) and patients who received RT/CT and tumor biopsy (F). Kaplan–Meier survival analysis of GBhisto (G) and GBmol (H) subject to MGMT promoter methylation status (all patients treated with RT/CT). Univariate (I) and multivariate (J) Cox proportional Hazards Model of the entire cohorts GBmol + GBhisto. Variables that reached statistical significance (P < .05) in univariate log-rank test were subjected to multivariate analysis.
See this image and copyright information in PMC

References

    1. WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon: International Agency for Research on Cancer; 2021. (WHO Classification of Tumours Series, 5th ed.; Vol. 6). https://publications.iarc.fr/601.
    1. Brat DJ, Aldape K, Colman H, et al.. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136(5):805–810. - PMC - PubMed
    1. Tesileanu CMS, Sanson M, Wick W, et al.. Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the EORTC randomized phase III CATNON Trial. Clin Cancer Res. 2022;28(12):2527–2535. - PMC - PubMed
    1. Berzero G, Di Stefano AL, Ronchi S, et al.. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro-Oncology. 2021;23(6):955–966. - PMC - PubMed
    1. Wijnenga MMJ, Maas SLN, van Dis V, et al.. Glioblastoma lacking necrosis or vascular proliferations: different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation. Neurooncol Adv. 2023;5(1):vdad075. - PMC - PubMed

LinkOut - more resources